logo.png
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
February 23, 2021 08:00 ET | Cabaletta Bio
PHILADELPHIA, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
logo.png
Cabaletta Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 07, 2021 08:00 ET | Cabaletta Bio
PHILADELPHIA, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
logo.png
Cabaletta Bio to Participate in Upcoming January Investor Conferences
January 04, 2021 08:00 ET | Cabaletta Bio
PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
logo.png
Cabaletta Bio Announces First Patient Dosed in Landmark DesCAARTes™ Trial of DSG3-CAART for Treatment of Mucosal-Dominant Pemphigus Vulgaris
December 08, 2020 16:30 ET | Cabaletta Bio
First patient ever infused with a CAAR (chimeric autoantibody receptor) T cell therapy product candidate expands the potential clinical application of CAR T technology beyond cancer into autoimmune...
logo.png
Cabaletta Bio to Participate in Upcoming December Investor Conferences
November 23, 2020 08:00 ET | Cabaletta Bio
PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
logo.png
Cabaletta Bio Reports Third Quarter 2020 Financial Results and Provides Business Update
November 10, 2020 07:30 ET | Cabaletta Bio
PHILADELPHIA, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
logo.png
Cabaletta Bio to Present at Upcoming Investor Conferences in October
September 25, 2020 08:00 ET | Cabaletta Bio
PHILADELPHIA, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies...
logo.png
Cabaletta Bio to Present at Multiple Upcoming September Investor Conferences
September 08, 2020 08:00 ET | Cabaletta Bio
PHILADELPHIA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies...
logo.png
Cabaletta Bio Announces Publication of Comprehensive Preclinical Study Results for DSG3-CAART in Pemphigus Vulgaris
August 25, 2020 08:00 ET | Cabaletta Bio
DSG3-CAART achieved autoantibody elimination and resolution of blisters in active immune mouse model of pemphigus vulgarisSoluble autoantibodies demonstrated potential to enhance DSG3-CAART efficacy...
logo.png
Cabaletta Bio Reports Second Quarter 2020 Financial Results and Provides Business Update 
August 06, 2020 07:30 ET | Cabaletta Bio
PHILADELPHIA, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...